CoChat

Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin

Open access
Lakoski, Susan G., Xu, Fang, Vega, Gloria L., Grundy, Scott M., Chandalia, Manisha, Lam, Chun, Lowe, Robert S., Stepanavage, Michael E., Musliner, Thomas A., Cohen, Jonathan C., Hobbs, Helen H. · 2010 · The Journal of Clinical Endocrinology & Metabolism
Cited by 74

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

CONTEXT: The level and duration of exposure to circulating low-density lipoprotein-cholesterol (LDL-C) are major contributors to coronary atherosclerosis. Therefore, optimal prevention will require long-term LDL-C reduction, making it important to select the most effective agent for each individual. OBJECTIVE: We tested the hypothesis that individuals with high fractional absorption of cholesterol respond better to the cholesterol absorption inhibitor ezetimibe than to simvastatin, whereas low absorbers, who have elevated rates of cholesterol synthesis, respond better to simvastatin. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled, crossover trial was performed in 215 African- and European-American men. INTERVENTION: Participants were randomized to placebo, ezetimibe (10 mg/d), simvastatin (10 mg/d), and both drugs for 6 wk each. MAIN OUTCOME: Plasma levels of LDL-C, surrogate markers for cholesterol absorption (campesterol) and synthesis (lathosterol), and proprotein convertase subtilisin-like kexin type 9 were measured at baseline and after treatment. RESULTS: LDL-C levels were reduced by 19% (ezetimibe), 25% (simvastatin), and 41% (ezetimibe+simvastatin) from a baseline of 146 +/- 20 mg/dl; results were similar between ethnic groups. Reduction in LDL-C correlated poorly with baseline levels of noncholesterol sterols and proprotein convertase subtilisin-like kexin type 9. Although individual responses varied widely, change in LDL-C on ezetimibe correlated with response to simvastatin (r = 0.46, P < 0.001). Combination therapy lowered LDL-C by 15% or greater in more than 95% of participants. CONCLUSIONS: Baseline cholesterol absorption and synthesis did not predict responsiveness to LDL-lowering drugs. Responsiveness to simvastatin and ezetimibe were highly correlated, suggesting that factors downstream of the primary sites of action of these drugs are a major determinant of response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1952

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 74

Metadata

Authors
Lakoski, S. G., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., Cohen, J. C., & Hobbs, H. H.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2010-02-01
Volume
95
Issue
2
Pages
800-809
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1989492995
Cited by
74
References
3
FWCI
5.84
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. https://app.cochat.ai/papers/10.1210/jc.2009-1952
The paper
Lakoski, S. G., Xu, F., Vega, G. L., Grundy, S. M., Chandalia, M., Lam, C., Lowe, R. S., Stepanavage, M. E., Musliner, T. A., Cohen, J. C., & Hobbs, H. H. (2010). Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2009-1952

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.